Predictive Role of Preoperative Whole-Body 18F-FDG PET/CT for Risk Stratification of Early-Stage (FIGO I-IIA) Cervical Cancer Patients Treated by Surgery

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jan 29

PMID 38283777

Authors

Nagesh Kumar Singaram

Narendra Hulikal

Ranadheer Manthri

Amith Kumar Chowhan

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of the present study was to investigate the predictive value of maximum standardized uptake value (SUV) measured on preoperative F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (F-FDG PET/CT) in International Federation of Gynecology and Obstetrics (FIGO 2009) stage I-IIA cervical cancer patients who were treated with radical hysterectomy.

Methods: A total of 47 patients with FIGO stage I-IIA cervical cancer who were evaluated preoperatively with biopsy and F-FDG PET/CT followed by radical hysterectomy were included in the study. Correlation between SUV and pathological risk factors or survival was studied.

Results: The mean SUV was significantly higher in patients with large tumor size (≥4 cm), advanced stage (IIA>IB>IA) and depth of invasion >50%. No significant difference was noted in SUV between patients with and without pelvic lymph node involvement (P=0.639). SUV of the primary tumor with and without lymph-vascular invasion were 12.95 and 10.35, respectively (P=0.5). No significant difference was noted between patients with high SUV and low SUV with regards to overall survival (OS) and disease-free survival (DFS), using an optimal cut-off value of 7.65 for OS and DFS obtained from receiver operating characteristic (ROC) curve analysis. Patient with tumor size >4cm had 5.9 times more probability of mortality compared to tumor size <4cm (P=0.09).

Conclusion: The present study observations showed that although SUV is associated with pathological variables, it does not independently predict oncological outcomes in FIGO stage IA-IIA cervical cancer patients who were treated with radical hysterectomy. These findings suggest that SUV of primary tumor may be used for risk stratification, but not for prognostication in surgically treated early-stage cervical cancer patients. Not using other parameters of F-FDG PET/CT like metabolic tumor volume (MTV), tumor lysis glycolysis (TLG), small sample size, variation in calculation of SUV, histopathologic heterogeneity, inclusion of stage IA patients in the study were constraints of present study. Further studies with large sample size using multi metabolic parameters of F-FDG PET/CT, including the SUV,SUV,SUV, MTV and TLG are needed.

References

Ryu H, Chun M, Chang K, Chang H, Lee J . Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol. 2005; 96(2):490-5. DOI: 10.1016/j.ygyno.2004.10.038. View

Lee Y, Choi C, Kim C, Kang H, Kim T, Lee J . The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol. 2009; 115(1):65-68. DOI: 10.1016/j.ygyno.2009.06.022. View

Yagi S, Yahata T, Mabuchi Y, Tanizaki Y, Kobayashi A, Shiro M . Primary tumor SUV on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy. Mol Clin Oncol. 2016; 5(3):216-222. PMC: 4997975. DOI: 10.3892/mco.2016.953. View

Al-Ibraheem A, Alsharif A, Abu-Hijlih R, Jaradat I, Mansour A . Clinical Impact of F-FDG PET/CT on the Management of Gynecologic Cancers: One Center Experience. Asia Ocean J Nucl Med Biol. 2019; 7(1):7-12. PMC: 6352047. DOI: 10.22038/AOJNMB.2018.11208. View

Xu W, Yu S, Xin J, Guo Q . Relationship of 18F-FDG PET/CT metabolic, clinical and pathological characteristics of primary squamous cell carcinoma of the cervix. J Investig Med. 2016; 64(8):1246-1251. DOI: 10.1136/jim-2016-000166. View

Nakamura K, Hongo A, Kodama J, Hiramatsu Y . The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer. Gynecol Oncol. 2011; 123(1):82-7. DOI: 10.1016/j.ygyno.2011.06.026. View

Takekuma M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N . Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer. J Obstet Gynaecol Res. 2015; 41(10):1638-43. DOI: 10.1111/jog.12754. View

Pecorelli S, Zigliani L, Odicino F . Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009; 105(2):107-8. DOI: 10.1016/j.ijgo.2009.02.009. View

Singh N, Arif S . Histopathologic parameters of prognosis in cervical cancer--a review. Int J Gynecol Cancer. 2004; 14(5):741-50. DOI: 10.1111/j.1048-891X.2004.014504.x. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y . Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer. 2009; 100(9):1400-5. PMC: 2694432. DOI: 10.1038/sj.bjc.6605048. View

12.

Yun M, Kim S, Pak K, Lee C . Additional Prognostic Value of SUVmax Measured by F-18 FDG PET/CT over Biological Marker Expressions in Surgically Resected Cervical Cancer Patients. Oncol Res Treat. 2015; 38(9):413-6. DOI: 10.1159/000438959. View

13.

Tanizaki Y, Kobayashi A, Shiro M, Ota N, Takano R, Mabuchi Y . Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer. Int J Gynecol Cancer. 2014; 24(3):454-60. DOI: 10.1097/IGC.0000000000000074. View

14.

Kidd E, Siegel B, Dehdashti F, Rader J, Mutch D, Powell M . Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol. 2010; 28(12):2108-13. DOI: 10.1200/JCO.2009.25.4151. View

15.

Zhang L, Sun H, Du S, Xu W, Xin J, Guo Q . Evaluation of 18F-FDG PET/CT parameters for reflection of aggressiveness and prediction of prognosis in early-stage cervical cancer. Nucl Med Commun. 2018; 39(11):1045-1052. DOI: 10.1097/MNM.0000000000000909. View

16.

Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H . Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 2003; 81(12):1144-51. DOI: 10.1034/j.1600-0412.2002.811208.x. View

17.

Yu L, Jia C, Wang X, Lu P, Tian M, Wang W . Evaluation of ¹⁸F-FDG PET/CT in early-stage cervical carcinoma. Am J Med Sci. 2010; 341(2):96-100. DOI: 10.1097/MAJ.0b013e3181f48df6. View

18.

Kyung M, Kim H, Seoung J, Choi I, Joo Y, Lee M . Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis. Oncol Lett. 2015; 9(5):2218-2224. PMC: 4467330. DOI: 10.3892/ol.2015.3015. View

19.

Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K . Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012; 39(5):840-5. DOI: 10.1007/s00259-011-2057-9. View

20.

Antonsen S, Loft A, Fisker R, Nielsen A, Andersen E, Hogdall E . SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecol Oncol. 2013; 129(2):298-303. DOI: 10.1016/j.ygyno.2013.01.019. View